BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.
Email Alerts
Email Alerts
Recent BDSI News
BioDelivery Sciences Reports Strong Q2 2020 Results
August 5, 2020
Second Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million BELBUCA and Symproic® Each Reach All Time High TRx Volume and Market Share Conference Call and Webcast Scheduled for 8:30 AM ...
BioDelivery Sciences to Report Second Quarter 2020 Financial Results on August 5, 2020
July 27, 2020
RALEIGH, N.C. , July 27, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2020 ...
BioDelivery Sciences to Present at Two Upcoming Investor Conferences
May 29, 2020
RALEIGH, N.C. , May 29, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive ...